October 5-7, 2026

Join us at Meeting on the Mesa

Cencora is proud to be a diamond sponsor and excited to connect with you at the 2026 Cell & Gene Meeting on the Mesa this October. Come visit us at exhibit table F5 to talk with our experts about the challenges and advancements in cell and gene therapies. 

Our solutions that support advanced therapies

Full lifecycle support for advanced therapies

At Cencora, we are at the forefront of advancing cell and gene therapies, offering comprehensive, integrated support that spans the entire product lifecycle. With a legacy of successfully bringing complex and transformative therapies to market globally, we combine deep regulatory expertise, strategic consulting, and specialized logistics to help our clients navigate the intricacies of development and commercialization. Our tailored solutions address the unique challenges of advanced therapies, helping to ensure that innovative treatments reach those who need them most.

A comprehensive specialty cell and gene supply chain solution

Cell and gene therapy (CGT) logistics demand a highly specialized and carefully managed supply chain. From transporting delicate cells and genes safely and efficiently at precise temperatures to moving critical patient samples back to the lab, every step must be meticulously planned and executed. The stakes are high, with no room for error. At Cencora, we provide a comprehensive supply chain solution specifically designed for cell, gene, and advanced therapies. Leveraging our cutting-edge cryogenic infrastructure and proven methodologies, we simplify even the most complex logistical challenges

Cell and gene therapy resources

Cell and gene therapy commercialization handbook: Key strategies to help address market challenges

Cell and gene therapy playbook for payer engagement: Translating payer expectations into actionable market access strategies

Closing the readiness gap for CGTs in community-based care

Connect with our cell and gene experts

Schedule some time with our cell and gene experts today. We look forward to hearing from you.
Abstract